Impacts to Anxiety, Depression, and Psycho-Spiritual Metrics after Ketamine-Assisted Psychotherapy in Palliative Care Patients at the AIMS Institute

Date of Award

2024

Document Type

Project

College/School

College of Nursing

Degree Name

Doctor of Nursing Practice (DNP)

Project Mentor

Therry Rose Eparwa

Readers

Conor Watters

Abstract

There is considerable evidence that palliative care patients disproportionately experience anxiety, depression, and existential distress related to their chronic illnesses. Additionally, conventional therapies tend to be less effective in the treatment of this patient population. As such, research is being conducted into novel therapies. One of the promising therapies currently under active investigation is ketamine-assisted psychotherapy (KAP) which involves a combination of the administration of the dissociative anesthetic ketamine combined with psychotherapy.

Two clinical trials are being conducted at the Advanced Integrative Medical Sciences (AIMS) Institute in Seattle, WA, the purposes of which are to evaluate integrative care for patients with cancer and/or chronic medical conditions. A subset of the clinical trial participants were selected based upon palliative care criteria and their KAP-related data extracted for analysis. The study described herein used that data to assess the efficacy of KAP in ameliorating anxiety, depression, and psycho-spiritual distress experienced by participants as a consequence of their chronic medical conditions.

The results showed that, following an initial KAP session, there were downward shifts in anxiety and depression as indicated by changes in score on the PHQ-9 and GAD-7 survey instruments. These shifts were moderate in size, with a z(27) = -2.75, 90.3% CI = [-6, 0] point shift in the PHQ-9 score and a z(27) = -4.25, 90.3% CI = [-1, -7] point shift in the GAD-7 score, respectively. They were statistically significant at a fixed analysis effects size value of 0.6 with p-values of 0.033 and 0.011. The NIH-HEALS data showed smaller shifts (z(24) = 3.25, 88.6% CI = [-2, 8]) that were not statistically significant at an effects size of 0.6 and p-value of 0.363. Analysis was also conducted to see if participants’ ACES and Resiliency scores were correlated with changes in the aforementioned instrument scores. Correlation was rejected at a statistically significant level for either ACEs or Resiliency scores for any of the survey instruments.

Caution should be used in interpreting these results, as sample sizes were relatively small and there were significant integrative therapy-based covariates that were not addressed in the analysis, thus precluding any attribution of causality to KAP.

Latest Blog Posts

Supporting women in the wild with science and wisdom about psychedelics.

Supporting women in the wild with science and wisdom about psychedelics.

Supporting women in the wild with science and wisdom about psychedelics. 134. Psychedelics and Grief: When Containment Stops Working Dr. Sunil Aggarwal joins April Pride to talk psilocybin, grief, and the difference between containing a loss and integrating it. April Pride Sep 29 Recently, it occurred to me that my relationship with trust needed tending. When I told a friend, she asked, “Why don’t you trust yourself?” I’ve been sitting with that question because it tracks and it confuses me at the same time. I’ve walked into divorce, entrepreneurship, and work in the Schedule I-adjacent world. Not the choices of ...

Read More
Watch now: Psychedelics and Grief: When Containment Stops Working

Watch now: Psychedelics and Grief: When Containment Stops Working

How Academy Members Are Integrating Psychedelics to Ease Distress Catherine Arnold For patients facing serious illness, some of the deepest suffering cannot be measured on a numerical scale.  Some patients experience anxiety that does not respond to conventional treatment, as well as a deep sense of demoralization, isolation, and loss of meaning. Palliative and hospice care have long recognized treatment of this existential distress as central to whole-person care. Now, an emerging field of research is asking whether psychedelic-assisted therapy (PAT)—a structured protocol that combines the administration of a psychoactive compound with guided professional psychotherapy before, during, and after the ...

Read More
Psychedelic science update & harm reduction training for naturopathic physicians

Psychedelic science update & harm reduction training for naturopathic physicians

8 CONTINUING EDUCATION (CE) HOURS FEBRUARY 1–4, 2027OPIHIHALE ETHNOBOTANICAL PRESERVEBig Island, Hawai‘i $2,850 INCLUDES Three nights lodging | All mealsGround transportation to and from Kona AirportCourse materials | Guided ethnobotanical tour AIMS Institute in collaboration with Opihihale Ethnobotanical Preserve WHY THIS COURSE? As interest in psychedelic therapies continues to grow, naturopathic physicians are increasingly asked about their safety, effectiveness, legal status, and appropriate clinical use. This immersive continuing education program provides an evidence-based review of current psychedelic science together with practical harm reduction strategies for clinicians whose patients are considering or using psychedelic medicines. Presented by the AIMS Institute in ...

Read More

Accessibility Tools

Increase TextIncrease Text
Decrease TextDecrease Text
GrayscaleGrayscale
Invert Colors
Readable FontReadable Font
Reset
Call Us Text Us